logo-loader
viewProactive Group

New York's BIO CEO & Investor conference brings biotech investors, companies and analysts together

Now in its 20th year, the conference brings investors, analysts, and management of companies together

1516828886_brooklyn-bridge-at-night.jpg
The conference is in New York

Hundreds of biotech investors are gearing up for one of the hottest events in the calendar - the BIO CEO & Investor conference in New York.

Now in its 20th year, it offers investors the chance to meet management from top public and private biotech firms, and for companies to present their stories.

It takes place from February 12 to 13 at the New York Marriott Marquis on Broadway. Get the details of the event HERE..

Firms featured..

Companies to be featured include Savara Inc (NASDAQ: SVRA), which raised nearly US$100mln in  2017 and has many near-term milestones for 2018.

The group is focused on novel therapies for the treatment of rare respiratory diseases and its late-stage pipeline includes: Molgradex, which is in Phase 3 trials for aPAP and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis.

Meanwhile, NewLink Genetics (NASDAQ: NLNK) is focused on  a very topical area of medicine - immuno-oncology.

The group is working on product candidates, which target the IDO pathway. IDO regulates immune function through control of tryptophan levels.

The firm expects imminent initiation of a Phase 3 trial in melanoma and a Phase 2 data readout in 2018 and it has reported promising early data in both AML and pancreatic cancer. 

It also has a collaboration with drugs major Astra Zeneca (LON:AZN) for a Phase 2 programme in pancreatic cancer.

Novel therapies..

Newron Pharmaceuticals  (SWX: NWRN) is another company presenting at the conference.

It is advancing novel therapies for diseases of the central and peripheral nervous system. It has received approval for Xadago (safinamide) for Parkinson’s disease in the EU, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon, in the US.

Newron is also developing has a pipeline of promising rare disease treatments including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. It also has Evenamide as the potential first add on therapy for the treatment of patients with positive symptoms of schizophrenia.

Elsewhere,  Integrity Applications Inc. (OTCQB: IGAP) is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes.

Private firms Xontogeny and Landos Biopharma will also be at the New York event.

The former is an accelerator firm focused on development and investment innovations that are too large for Angel investors but too small for the traditional venture capital route.

The latter is focused on development of first-in-class oral therapeutics for patients with autoimmune diseases using a novel pathway.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clear Leisure PLC to launch 'digital twins' projects for London and Milan

Clear Leisure PLC (LON:CLP) chairman and CEO of Francesco Gardin tells Proactive London's Andrew Scott they're to launch two projects to develop 'digital twins' for London and Milan.  He says digital twins of other UK and European cities are expected to follow. Gardin says  the...

36 minutes ago

3 min read